A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Merck Sharp & Dohme LLC
340 participants
May 22, 2026
INTERVENTIONAL
Conditions
Summary
Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This trial will compare MK-1045 to a standard immunotherapy called blinatumomab. The goals of this trial are to learn if more people who receive MK-1045 have no cancer cells in their bone marrow compared to people who receive blinatumomab and if people who receive MK-1045 live longer compared to people who receive blinatumomab.
Eligibility
Inclusion Criteria5
- Has a confirmed diagnosis of relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) with 5% or more lymphoblasts in the bone marrow.
- Has CD19+ disease, confirmed by local flow cytometry and/or immunohistochemistry testing at the time of enrollment.
- Has Philadelphia-negative disease, confirmed by testing, at the time of enrollment.
- Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART).
Exclusion Criteria12
- Has Burkitt's leukemia.
- History or presence of clinically relevant central nervous system (CNS) diseases such as epilepsy, hemorrhagic/ischemic stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, and psychosis.
- Has active acute graft versus host disease (GvHD), Grade 2 to 4 according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment.
- History of serious cardiovascular and cerebrovascular diseases.
- HIV-infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
- Received prior treatment with blinatumomab within 12 weeks for Part 1 and 24 weeks for Part 2 before the first dose of study intervention (individuals known to be refractory or intolerant to blinatumomab are to be excluded).
- Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- Known additional malignancy that is progressing or has required active treatment within the past 2 years.
- Isolated extramedullary disease (EMD).
- Active autoimmune disease unrelated to ALL that has required systemic treatment in the past 2 years or history of autoimmune disease with potential CNS involvement.
- Active infection requiring systemic therapy.
- Has not adequately recovered from major surgery or have ongoing surgical complications.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous administration
Intravenous administration
Oral administration as a premedication
Intravenous administration as a premedication
Intravenous administration as a premedication
Intravenous administration as a rescue medication
Intravenous administration as a rescue medication
Intravenous administration as a rescue medication
Intravenous administration as a rescue medication
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07570173